bio sketch column
Chas Bountra is Professor of Translational Medicine, Head of the Structural Genomics Consortium (SGC), Acting Director of BioEscalator, a Theme Lead in the Academic Health Science Network, and Director of Oxford Innovations at the University of Oxford. He has nearly three decades of academic and industrial experience in target identification, lead discovery, lead optimisation, and clinical trial design for several neuro-psychiatric, gastro-intestinal and inflammatory conditions. He has taken more than 40 novel molecules into Phase I and more than 20 into Phase II. Professor Bountra was the first to demonstrate the anti-emetic effects of NK1 antagonists, helped launch Alostetron for IBS, and recently helped a biotech develop a novel analgesic. He has now established the SGC as a world leading outfit for human protein structural biology, chemical biology, and ‘open’ target discovery. He was voted one of the top innovators in the industry in 2012 and is an invited expert on several government and charitable research funding bodies as well as the advisor for many academic, biotech, and pharma drug discovery programmes.